B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Public ClinicalTrials.gov record NCT04483778. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Study identification
- NCT ID
- NCT04483778
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Seattle Children's Hospital
- Other
- Enrollment
- 68 participants
Conditions and interventions
Conditions
- Carcinoma
- Clear Cell Sarcoma
- Desmoplastic Small Round Cell Tumor
- Ewing Sarcoma
- Germ Cell Tumor
- Hepatoblastoma
- Malignant Peripheral Nerve Sheath Tumors
- Melanoma
- Neuroblastoma
- Osteosarcoma
- Pediatric Solid Tumor
- Retinoblastoma
- Rhabdoid Tumor
- Rhabdomyosarcoma
- Soft Tissue Sarcoma
- Synovial Sarcoma
- Wilms Tumor
Interventions
- Pembrolizumab Drug
- second generation 4-1BBζ B7H3-EGFRt-DHFR Biological
- second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 0 Years to 26 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 12, 2020
- Primary completion
- Nov 30, 2040
- Completion
- Nov 30, 2040
- Last update posted
- Apr 27, 2026
2020 – 2040
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Seattle Children's Hospital | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04483778, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04483778 live on ClinicalTrials.gov.